Supplementary Material: Switching From Dupilumab to Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 52 Week Safety and Efficacy Results From an Open-Label Extension of the Phase 3 Heads Up Study
收藏Mendeley Data2026-07-04 收录
官方服务：
资源简介：
Switching From Dupilumab to Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 52-Week Efficacy and Safety Results From an Open-Label Extension of the Phase 3 Heads Up Study
创建时间：
2026-06-02
